Multiple Myeloma | Unmet Need | First-Line Transplant-Ineligible Multiple Myeloma | US/EU | 2018

Market Outlook

The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell transplantation (ASCT). Approximately one-quarter of diagnosed multiple myeloma patients are not eligible to undergo a transplant owing to their age and/or performance status. For years, melphalan-based regimens were the standard of care for these patients, but Celgene’s Revlimid and Thalomid/Thalidomide and Janssen/Takeda’s Velcade have revolutionized the treatment of transplant-ineligible multiple myeloma patients and are now the cornerstones of therapy. Nevertheless, because of the older age and comorbidities of most ASCT-ineligible patients, physicians must focus on treating the symptoms of the disease while managing the toxicity of treatment and improving patients’ quality of life. Thus, significant unmet need remains for well-tolerated agents that can also delay disease progression and extend the survival of this frail patient subpopulation.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals that are most likely to influence a therapy’s uptake for transplant-ineligible multiple myeloma?
  • How do current therapies perform on key clinical drug attributes for this patient population?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European hematologist-oncologists when considering hypothetical new treatment options for first-line transplant-ineligible multiple myeloma?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

SCOPE OF THE REPORT

  • Markets covered: United States, France, Germany, United Kingdom
  • Primary research: Survey of 60 hematologist-oncologists in the United States and 30 medical oncologists in Europe
  • Key companies: Celgene, Janssen, Takeda
  • Key drugs: Revlimid, Velcade, Thalomid/Thalidomide Celgene
  • Key metrics included:
    • Stated versus derived analysis of U.S. and European physician prescribing behavior.
    • Conjoint analysis with U.S. and European physicians, includes market simulator.
    • Assessment of current drug performance against treatment drivers and goals.
    • Physician perceptions of unmet need in disease/subpopulation covered and related diseases/subpopulations. Analysis of remaining drug development opportunities.
Login to access report